NO20060091L - Anvendelse av kondenserte heterocykliske forbindelser som SCCE-inhibitorer for behandling av hudproblemer eller kreft - Google Patents
Anvendelse av kondenserte heterocykliske forbindelser som SCCE-inhibitorer for behandling av hudproblemer eller kreftInfo
- Publication number
- NO20060091L NO20060091L NO20060091A NO20060091A NO20060091L NO 20060091 L NO20060091 L NO 20060091L NO 20060091 A NO20060091 A NO 20060091A NO 20060091 A NO20060091 A NO 20060091A NO 20060091 L NO20060091 L NO 20060091L
- Authority
- NO
- Norway
- Prior art keywords
- cancer
- treatment
- skin problems
- scce
- condensed heterocycles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Det beskrives heterosykliske inhibitorer av stratumcorneurnkymotryptisk enzym (SCCE). Mer spesielt beskrives anvendelsen av forbindelser med formel (I) eller (II) for behandling av visse sykdommer og særlig hudsykdommer som pruritt og også cancer som ovariecancer.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200300840 | 2003-06-06 | ||
DKPA200300844 | 2003-06-06 | ||
DKPA200300842 | 2003-06-06 | ||
DKPA200300843 | 2003-06-06 | ||
PCT/DK2004/000388 WO2004108139A2 (en) | 2003-06-06 | 2004-06-07 | Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20060091L true NO20060091L (no) | 2006-03-06 |
Family
ID=33514772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060091A NO20060091L (no) | 2003-06-06 | 2006-01-06 | Anvendelse av kondenserte heterocykliske forbindelser som SCCE-inhibitorer for behandling av hudproblemer eller kreft |
Country Status (18)
Country | Link |
---|---|
US (1) | US7872052B2 (no) |
EP (1) | EP1631295B1 (no) |
JP (1) | JP5044214B2 (no) |
KR (2) | KR101099409B1 (no) |
CN (1) | CN101152185B (no) |
AT (1) | ATE459359T1 (no) |
CA (1) | CA2525383C (no) |
CY (1) | CY1110084T1 (no) |
DE (1) | DE602004025803D1 (no) |
DK (1) | DK1631295T3 (no) |
ES (1) | ES2341545T3 (no) |
HK (2) | HK1091731A1 (no) |
NO (1) | NO20060091L (no) |
NZ (1) | NZ543636A (no) |
PL (1) | PL1631295T3 (no) |
PT (1) | PT1631295E (no) |
SI (1) | SI1631295T1 (no) |
WO (1) | WO2004108139A2 (no) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
DE10320785A1 (de) * | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
US8044060B2 (en) | 2003-05-09 | 2011-10-25 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory |
DE102004001873A1 (de) * | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
KR101431279B1 (ko) * | 2005-07-29 | 2014-08-20 | 리스버로직스 코퍼레이션 | 복합 질환의 예방 및 치료용 약학적 조성물 및 삽입가능한의료 장치에 의한 이의 전달 |
PL2066662T3 (pl) | 2006-09-21 | 2013-05-31 | Kyorin Seiyaku Kk | Inhibitory hydrolaz serynowych |
JP2010505811A (ja) | 2006-10-04 | 2010-02-25 | ファイザー・プロダクツ・インク | カルシウム受容体アンタゴニストとしてのピリド[4,3−d]ピリミジン−4(3H)−オン誘導体 |
ES2454966T3 (es) | 2007-02-01 | 2014-04-14 | Resverlogix Corp. | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
PT2183273T (pt) | 2007-08-17 | 2017-05-22 | Novartis Ag | Depsipéptidos cíclicos |
US8415305B2 (en) | 2007-08-17 | 2013-04-09 | Novartis Ag | Use of cyclic depsipeptides to inhibit kallikrein 7 |
JP5498392B2 (ja) | 2007-11-30 | 2014-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 1,5−ジヒドロ−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体及びcns障害の治療のためのpde9aモジュレーターとしてのそれらの使用 |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
NZ590788A (en) | 2008-09-08 | 2012-11-30 | Boehringer Ingelheim Int | Pyrazolopyrimidines and their use for the treatment of cns disorders |
WO2010079431A2 (en) | 2009-01-08 | 2010-07-15 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
EP2403857B1 (en) * | 2009-03-05 | 2013-12-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidine as cdc7 kinase inhibitors |
NZ595747A (en) | 2009-03-18 | 2015-06-26 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
MX2011010184A (es) | 2009-03-31 | 2011-10-28 | Boehringer Ingelheim Int | Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4 -ona y su uso como moduladores de pde9a. |
KR20190091564A (ko) | 2009-04-22 | 2019-08-06 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
TWI419884B (zh) * | 2010-06-24 | 2013-12-21 | Univ Chang Gung | 苯并雜氧嗪酮衍生物,其製備方法以及包含有此等衍生物的藥學組成物 |
CN105541849B (zh) | 2010-08-12 | 2018-03-23 | 勃林格殷格翰国际有限公司 | 6‑环烷基‑1,5‑二氢‑吡唑并[3,4‑d]嘧啶‑4‑酮衍生物及其作为PDE9A抑制剂的用途 |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
US8680054B2 (en) | 2011-04-20 | 2014-03-25 | Novartis Ag | Suspension type topical formulations comprising cyclic depsipeptide |
US8614289B2 (en) | 2011-04-20 | 2013-12-24 | Novartis Ag | Processes for the manufacture of macrocyclic depsipeptides and new intermediates |
PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
RU2014141674A (ru) | 2012-03-16 | 2016-05-10 | Аксикин Фармасьютикалз, Инк. | 3,5-диаминопиразоловые ингибиторы киназы |
CN107383009B (zh) | 2012-06-13 | 2020-06-09 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US8987413B2 (en) | 2012-10-09 | 2015-03-24 | Novartis Ag | Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates |
US9067978B2 (en) | 2012-10-09 | 2015-06-30 | Novartis Ag | Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
SG11201508328PA (en) | 2013-04-19 | 2015-11-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
US9744148B2 (en) | 2014-01-23 | 2017-08-29 | Sixera Pharma Ab | Kallikrein 7 inhibitors |
SI3097085T1 (sl) * | 2014-01-23 | 2020-11-30 | Sixera Pharma Ab | Derivati benzoksazinona za zdravljenje kožnih bolezni |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
UA118312C2 (uk) | 2014-12-23 | 2018-12-26 | Ексікін Фармасутікалз, Інк. | 3,5-діамінопіразолові інгібітори кінази |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
CN107438607B (zh) | 2015-02-20 | 2021-02-05 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
WO2019074979A1 (en) | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
WO2019074981A1 (en) * | 2017-10-09 | 2019-04-18 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
CN108421034A (zh) * | 2018-04-24 | 2018-08-21 | 济南磐升生物技术有限公司 | 激肽释放酶7在皮肤创伤愈合中的应用 |
AU2019262195B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
KR20210150476A (ko) | 2019-04-09 | 2021-12-10 | 누베이션 바이오 인크. | 헤테로시클릭 화합물 및 그의 용도 |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CA3151626A1 (en) | 2019-10-01 | 2021-04-08 | Molecular Skin Therapeutics, Inc. | Benzoxazinone compounds as klk5/7 dual inhibitors |
JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Fgfr阻害剤としての二環式複素環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
JP7502945B2 (ja) | 2020-09-08 | 2024-06-19 | 花王株式会社 | デリケートエリアのかぶれの検査方法 |
US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
EP4346761A1 (en) | 2021-06-01 | 2024-04-10 | Sixera Pharma AB | Oil-in-water emulsion of 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,l-benzoxazin-4-one |
JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Fgfr阻害剤としての三環式ヘテロ環 |
WO2023250321A1 (en) * | 2022-06-21 | 2023-12-28 | Dana-Farber Cancer Institute, Inc. | Fused bicyclic egfr inhibitors and methods of use thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1153994A (en) * | 1965-07-21 | 1969-06-04 | Aspro Nicholas Ltd | Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them |
FR2121341A1 (en) * | 1971-01-04 | 1972-08-25 | Ferlux | 2-substd-3,1-benzoxazin-4-ones - antiinflammatories, analgesics sedatives and diuretics |
IT1050750B (it) * | 1975-12-05 | 1981-03-20 | Erba Carlo Spa | Derivati della 3.4 di idro chinazolina |
JPS5576868A (en) | 1978-12-01 | 1980-06-10 | Hisamitsu Pharmaceut Co Inc | Novel 3,1-bezoxazine derivative |
GB8817651D0 (en) * | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
WO1990006921A1 (en) | 1988-12-21 | 1990-06-28 | The Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
AU635403B2 (en) * | 1990-02-15 | 1993-03-18 | Teijin Limited | 4h-3,1-benzoxazin-4-one compound and elastase inhibitor composition containing the same |
JPH07316056A (ja) * | 1990-02-15 | 1995-12-05 | Teijin Ltd | エラスターゼ阻害用医薬組成物 |
DK0525123T3 (da) * | 1990-06-20 | 1998-05-04 | Upjohn Co | Antiatherosklerotiske og antithrombotiske 1-benzopyran-4-oner og 2-amino-1,3-benzoxazin-4-oner |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5346886A (en) * | 1993-11-15 | 1994-09-13 | John Lezdey | Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin |
WO2000030646A1 (en) * | 1998-11-26 | 2000-06-02 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
WO2001017564A2 (en) * | 1999-09-10 | 2001-03-15 | The Procter & Gamble Company | Enzyme inhibitors |
EP1367886B1 (en) | 2001-02-09 | 2011-07-13 | Torbjörn Egelrud | Scce transgenic mice and their use as models of human disease |
AU2002317377A1 (en) * | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
US20060229324A1 (en) * | 2002-10-03 | 2006-10-12 | Akiko Itai | Quinazolin-4-one derivatives |
WO2004041755A2 (en) * | 2002-11-04 | 2004-05-21 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
-
2004
- 2004-06-07 CA CA2525383A patent/CA2525383C/en not_active Expired - Fee Related
- 2004-06-07 WO PCT/DK2004/000388 patent/WO2004108139A2/en active Application Filing
- 2004-06-07 EP EP04736195A patent/EP1631295B1/en not_active Expired - Lifetime
- 2004-06-07 NZ NZ543636A patent/NZ543636A/en not_active IP Right Cessation
- 2004-06-07 ES ES04736195T patent/ES2341545T3/es not_active Expired - Lifetime
- 2004-06-07 JP JP2006508134A patent/JP5044214B2/ja not_active Expired - Fee Related
- 2004-06-07 DE DE602004025803T patent/DE602004025803D1/de not_active Expired - Lifetime
- 2004-06-07 US US10/559,322 patent/US7872052B2/en active Active
- 2004-06-07 PT PT04736195T patent/PT1631295E/pt unknown
- 2004-06-07 CN CN2007101613027A patent/CN101152185B/zh not_active Expired - Fee Related
- 2004-06-07 KR KR1020057023349A patent/KR101099409B1/ko not_active IP Right Cessation
- 2004-06-07 AT AT04736195T patent/ATE459359T1/de active
- 2004-06-07 KR KR1020117022051A patent/KR101205257B1/ko not_active IP Right Cessation
- 2004-06-07 SI SI200431406T patent/SI1631295T1/sl unknown
- 2004-06-07 DK DK04736195.1T patent/DK1631295T3/da active
- 2004-06-07 PL PL04736195T patent/PL1631295T3/pl unknown
-
2006
- 2006-01-06 NO NO20060091A patent/NO20060091L/no not_active Application Discontinuation
- 2006-11-08 HK HK06112281.7A patent/HK1091731A1/xx not_active IP Right Cessation
-
2008
- 2008-09-25 HK HK08110652.0A patent/HK1120209A1/xx not_active IP Right Cessation
-
2010
- 2010-05-21 CY CY20101100450T patent/CY1110084T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN101152185A (zh) | 2008-04-02 |
AU2004244704A1 (en) | 2004-12-16 |
KR101205257B1 (ko) | 2012-11-27 |
ES2341545T3 (es) | 2010-06-22 |
CN101152185B (zh) | 2010-12-08 |
HK1091731A1 (en) | 2007-01-26 |
KR20110120960A (ko) | 2011-11-04 |
NZ543636A (en) | 2009-07-31 |
US20060258651A1 (en) | 2006-11-16 |
PL1631295T3 (pl) | 2010-09-30 |
DK1631295T3 (da) | 2010-06-21 |
JP5044214B2 (ja) | 2012-10-10 |
JP2006526581A (ja) | 2006-11-24 |
SI1631295T1 (sl) | 2010-06-30 |
WO2004108139A2 (en) | 2004-12-16 |
CA2525383C (en) | 2012-03-06 |
WO2004108139A3 (en) | 2005-03-10 |
CY1110084T1 (el) | 2015-01-14 |
DE602004025803D1 (de) | 2010-04-15 |
KR20060008331A (ko) | 2006-01-26 |
EP1631295B1 (en) | 2010-03-03 |
KR101099409B1 (ko) | 2011-12-27 |
WO2004108139A8 (en) | 2005-04-28 |
HK1120209A1 (en) | 2009-03-27 |
EP1631295A2 (en) | 2006-03-08 |
ATE459359T1 (de) | 2010-03-15 |
PT1631295E (pt) | 2010-05-24 |
CA2525383A1 (en) | 2004-12-16 |
US7872052B2 (en) | 2011-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060091L (no) | Anvendelse av kondenserte heterocykliske forbindelser som SCCE-inhibitorer for behandling av hudproblemer eller kreft | |
NO20065148L (no) | Monocykliske heterocykler som kinase inhibitorer | |
EA200601391A1 (ru) | Производные хинолина для применения в качестве микобактериальных ингибиторов | |
NO20081636L (no) | FAP - inhibitorer | |
EA200702048A1 (ru) | Фармакокинетически улучшенные соединения | |
EA200800555A1 (ru) | Производные ксантина в качестве селективных агонистов hm74a | |
EA201000915A1 (ru) | Ингибиторы пролилгидроксилазы | |
TNSN08227A1 (en) | [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases. | |
EA200701771A1 (ru) | Низкомолекулярные ингибиторы mdm2 и их применение | |
DE50310516D1 (de) | Fredericamycin-derivate | |
ATE532781T1 (de) | 5-(acylamino)indazol-derivate als kinase- inhibitoren | |
EA200700096A1 (ru) | Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии | |
EA200700168A1 (ru) | Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы | |
EA200801291A1 (ru) | Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ | |
EA201070247A1 (ru) | Ингибиторы протеасом | |
ATE433981T1 (de) | Heterocyclische verbindungen | |
EA200870089A1 (ru) | Применение производных бензоконденсированного гетероциклического сульфамида для лечения злоупотребления психоактивным веществом и аддикции | |
EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
BRPI0512049A (pt) | usos antivirais de complexos de ácido borìnico | |
UA85087C2 (en) | Monocyclic heterocycles as kinase inhibitors | |
EA201170828A1 (ru) | Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза | |
TNSN06260A1 (en) | Process for the preparation of tryptase inhibitors | |
ATE549024T1 (de) | Chinazolin-kaliumkanalhemmer | |
ATE443044T1 (de) | Tace inhibitoren | |
EA200600601A1 (ru) | Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |